asininityandbeyond

@SeanDentBsc No, they were rightly tight lipped Ruairidh did make a comment referring to biopsies which implied confidence in getting them (recognising they are optional) The new indications, high profile science day, Dr Spira’s confidence etc are all tells that things are going to plan IMO

@asininitybeyond Hey 👋 Ah I see, makes sense. For a moment there I thought the team had let slip some new biopsy data 👀 All the best 👍

Science day… Same old, same old? Maybe share price-wise but more meaningful in terms of intangibles, IMO. My first time at an #AVCT investor meeting in person - I live at least one border away from Piccadilly! Overall, lots of familiar content but some key additions. 1/6

@SeanDentBsc Hi Sean, it was laboured that AVA6000 went from 4:1 to 100:1 from mouse to human. Mice have much more free FAP in plasma than man, leading to more cleavage in the blood stream. 6103 is already 99:1 in mice, so could be significantly higher in human, reading across from A6K.

@asininitybeyond Hi AAB, what makes you say it looks like the TP ratio will be better in 6103 than 6000? I wasn't there (wish i was), I live at least 1 international border away 😅

✅ #AVCT’s tech is dynamite ✅ Team is absurdly talented ✅ there’s a maturity to (pre)clinical + commercial progress ✅ taking time to do it right will pay back ✅ FDA = a friendly counterparty ✅ independent doctors are excited about 6103 ✅ Nearterm: data + IP (+ deals?) 6/6

- Richard Hughes was there facing off with investors… it’s a Science Day, he didn’t need to be. Easy to tell ppl they should get to meetings in person but I know myself it’s hard for many. So my somewhat independent take on #AVCT’s Science Day is: 5/6

Interestingly, 6103 poster refers to DU145 prostate cancer; a PSA + PMSA negative subtype, so traditional Tx dont work. AVA6103 presents opportunity for primary + CUP Staggering potential here - CUP success is both hugely lucrative + the pinnacle of platform valuation. 3/3 #AVCT

CUP has massive unmet need + with no specific Tx. A drug with the ability to target a range of indications based on FAP + a broad utility warhead like EXd is perfect for this. Opens up ODD, accelerated pathways for AVA6103, plus a big Ph2 patient population.2/3 #AVCT

Its becoming more likely #AVCT is setting up for a Cancer of Unknown Primary (CUP) component to the AVA6103 trial in Ph2 IMO Suite of indications proving broad efficacy supports that, coupled with in-scope adeno + SC carcinoma histologies making up the majority of CUP cases.1/3

$LLY acquires CAR-T myeloma focussed Kelonia for up to $7bn. $3.5bn u/f + rest depends on milestones Lead asset Ph1, <40 pts dosed Platform tech ➡️ immediate read across to preCISION from Jake “we want the next Enhertu” Van Naarden - simplicity, turn-key, broad potential #AVCT

Revolution raises $2bn. Upsized 100% vs initial target of $1bn - placing shares issued at $142. Little to no discount. Good data opens so many doors. #AVCT

Lilly acquire Crossbridge Bio for $300m. Lead asset is a dual payload “potential best-in-class TROP2-targeting TOP1i/ATRi ADC” PRE-IND stage tech. Very straight forward read across for the value disconnect with #AVCT. businesswire.com/news/home/2026…

“Daraxonrasib achieved OS of 13.2 months compared to 6.7 months for chemotherapy.” - BioSpace “PFS doesn’t matter”, “Pharma only wants cures” narrative going right out the window. Giving patients more time really matters. Expect updated AVA6000 data this Q really shines. #AVCT

@BigBiteNow This stood out to me too: “Funding beyond inflection points” - #AVCT now has negotiating strength. “Substantial interest” - BP is motivated. “Multiple parties” - there is competition. “Partnering” - deal optionality. Plus, “100% ownership” ⬇️ - ‘partners’ want the lot?

This statement from today's #AVCT RNS supports the next leg higher. Macro influences aside, this is becoming THE year to be holding Avacta. "Our first, second and third generation assets are all attracting substantial interest from multiple parties for potential partnering. With our recent financing completed, we now have funding in place beyond multiple value inflection points through the rest of 2026 and we are excited about this potentially transformative period for the Company, delivering benefit for our patients and our shareholders alike."

#AVCT is building very nicely at the moment, supported by the growing time served for AVA6103 and evidence presented by the company. That evidence is currently merely crumbs, but the price action demonstrates the potential should more compelling evidence be presented or sufficient time elapse. The added fuel is the pending AVA6000 data signposted this quarter, which draws closer by the day. Long may it continue.

@Cumulus51896691 @RAH00084 I dug into it a while ago. I think this paper gives some answers. Albumin-AV6103 accumulation, yes - but also SPARC assisted uptake of Albumin bound molecule into TME. Same mechanisms used for Abraxane. This concept could also support oral delivery. mdpi.com/1999-4923/14/4…

@asininitybeyond @RAH00084 The missing bit to me is the albumin binding. This should extend circulation, and albumin tends to accumulate in tumours too. Yet to see a good account of this vis a vis the extended release profile. Looking forward to cornering Francis on the 6th.

#AVCT x.com/i/grok/share/e…

@RAH00084 Grok speaks of circulation pre + post 48 hour milestone. After 1 day its largely bound by FAP at the TME, then Exd released over time. Proves MoA via PK: if plasma is 6103 free but intermediate present >24h = PoC Apologies for the pedantry No arguments about the quality of AI!

@asininitybeyond Yes, technically it doesn’t “circulate longer in the blood” but I don’t think that’s what it is trying to say if you read the rest of it. Slight hallucination. Nevertheless a very impressive synopsis of AVA6103 via AI on many fronts. Was also far quicker than typing out myself!

@TonyRob70579912 @tom_the_bomb__ Not suggesting they disclose anything at a forum in Q2. Rather that the co already has data about drug performance, w/o biopsies or scans. And can share that with Pharma if compelled to do, as Terns did with Merck. So H2 not as meaningful a milestone for BP as it is for retail.

@asininitybeyond @tom_the_bomb__ At what forum will #avct disclose publicly the results you are predicting, in Q2?

Some nuggets on the Terns-$MRK deal from SEC fillings Merck/Terns had confidentially agreement in place since Sept 23. TO took place in March 26 Shows how long the “dating” stage can take. Expect #AVCT has been party to CA’s for a while given multiple mentions of partnering.1/4